Tag Archives: Rona Therapeutics

Rona Partners with Roche for ALK7-Targeting Asset; MetaVia Appoints New CMO; SAB-142 FDA Fast Track Designation

Three cardiometabolic-related news items have been observed: Rona Therapeutics entered into a partnership with Roche for an ALK7 asset to treat metabolic diseases (view press release); MetaVia appointed Sarah Browne as its new Chief Medical Officer (view press release); and SAB Bio received FDA Fast Track designation for the development of SAB-142 in Stage 3 T1DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Kailera Initiates H2H Study Vs. Semaglutide; Structure Initiates Ph1 Amylin Study; Rona Unveils Bivalent siRNA; Lilly Partners for Obesity Drug Discovery and Initiates Brenipatide Ph2 Bipolar Trial; Enveda Receives IND; ICER Obesity Report

A series of cardiometabolic-related news items has been observed from Kailera Therapeutics, Structure Therapeutics, Rona Therapeutics, Lilly, Enveda, and ICER. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here